In some of these models, the activity of immunotherapy has been adapted by incorporating the effect of activated tumor-specific cytotoxic CD8+ T cells responsible for tumor elimination together with the immune resistance response associated with the failure of many immunotherapeutic approaches, mainly due to the presence of tumor-infiltrating Treg. The gene discussed is CD8A; the disease is neoplasm.